YAP1 and neoplasm: YAP1 and its paralog TAZ, the transcriptional co-activators and downstream effectors of the Hippo pathway, share transcriptional programs driving malignant transformation, tumor progression [8], and a drug-tolerant cancer cell state, associated with resistance toward multiple targeted drugs, chemo-, and radiotherapies [9–11].